Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series

Barbolini Monica, Omarini Claudia, Toss Angela, Cortesi Giulia, Fiorani Claudia, Piombino Claudia, Dominici Massimo and Piacentini Federico

Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena, Italy
Division of Oncology, University Hospital of Modena, Italy
Division of Medical Oncology, University of Modena and Reggio Emilia, Italy

^*Correspondance to: Monica Barbolini 

 PDF  Full Text Case Series | Open Access

Abstract:

Abemaciclib is a cyclin-dependent 4/6 inhibitor approved by FDA in 2017 and by EMA in 2018 for treatment of hormone receptors positive, HER2 negative metastatic breast cancer in association with endocrine therapy. In 2019 FDA warned for a rare but severe lung inflammation possibly related to CDK 4/6 inhibitors. At the end of 2019 the world comes to know to a new corona virus
causing potential fatal lung injury. Here we report three different cases of interstitial lung disease in patients treated with Abemaciclib during SARS-CoV-2 pandemic at Modena Cancer Center.

Keywords:

COVID-19; Metastatic breast cancer; Abemaciclib; Interstitial lung disease

Cite the Article:

Monica B, Claudia O, Angela T, Giulia C, Claudia F, Claudia P, et al. Interstitial Lung Disease in Abemaciclibtreated Patients during SARS-CoV-2 Pandemic: A Case Series. Clin Oncol. 2020;5:1760..